Weekly Update: February 14, 2022
Seems like Putin’s sabre rattling is making people nervous…
Just like his march into Crimea and other minor incursions, it doesn’t take a PHD in geopolitical affairs to know that Putin is bent on annexing as much of the Old Soviet Union as possible even if it means doing it in bite sized pieces. If we (The US and NATO) Don’t man up and tell Putin straight up that his forces will be annihilated if he so much as puts a finger across any border this will go on forever and he is a master at creating the charade that somehow our side started something.
Until then the markets and everyone else will continue to be nervous.
Yahoo Finance 2-14-2022
Stock market news live updates: Stocks mixed as Russia-Ukraine conflict concerns rise
Stocks were mixed on Monday as investors eyed the escalating threat of Russian invasion in Ukraine alongside ongoing concerns over inflation and an aggressive move toward policy tightening by the Federal Reserve.
The S&P 500 fluctuated between small gains and losses after last week’s roller-coaster sessions on Thursday and Friday. Treasury yields rose and the 10-year yield hovered back near 2%.
Oil prices steadied after a recent run-up as Russia’s Foreign Minister Sergey Lavrov said he was urging Russian President Vladimir Putin to continue diplomatic talks. This came less than a day after U.S. officials signaled Russia could be nearing the launch of an invasion of Ukraine as soon as this week. National Security adviser Jake Sullivan told CNN on Sunday that “a major military action could begin by Russia in Ukraine any day now,” though the U.S. was still hoping for a diplomatic resolution. And these remarks in turn came after President Joe Biden held a phone call with Vladimir Putin on Saturday warning that the U.S. and its allies would “impose swift and severe costs” on Russia in the event of a military attack in Ukraine
The 21st Century Investment Bank Capital Raises + Strategic Advisory
Donald Capital is a boutique Investment Bank that focuses on raising capital for emerging growth companies in the U.S. and around the globe.
Ideally, we like to work with Private and Public companies with a good management team, a compelling business plan, and the ability to gain market share.
For more information go to: www.DonaldCapital-NY.com
The Premier Operating System for Publicly Traded Companies
Track your investors’ buying and selling behaviors and use those insights to engage them across marketing channels.
Know who’s buying and selling and monitor trading in real time. Unlock your shareholders contact info and build full contact profiles on your shareholders, including emails, phone numbers, and social media accounts to engage them and target new investors through media campaigns.
To schedule a demo email me at email@example.com or call 727-459-7378
2-14-22 Antibe Therapeutics Inc. OTC ATBF (TSXV:ATE)
Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results
– Acute pain clinical program for otenaproxesul initiating this quarter
– Ended quarter with a $59 million cash position
TORONTO, February 14, 2022–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2021.
“We’re excited to have launched otenaproxesul’s clinical program for post-operative pain and remain on track to begin Phase II in the fall. We’re also encouraged by draft guidance published last week by both the FDA and CDC, highlighting the urgent need for new non-opioid pain medications,” commented Dan Legault, Antibe’s CEO. “With our strong balance sheet, we’ve been able to advance multiple programs in parallel, including our inflammatory bowel disease program which targets a major need in an attractive market. At a corporate level, our disciplined approach to spending provides us with more than two years of cash runway. As the year progresses, we look forward to unlocking value for our shareholders as we achieve milestones across our development programs.”
2-2-2022 SRAX (NASDAQ: SRAX)
Replays Available From the Influential Companies of the 2022 Sequire Metals and Mining Conference
LOS ANGELES, Feb. 02, 2022 (GLOBE NEWSWIRE) — via InvestorWire – SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, hosted the 2022 Sequire Metals & Mining Conference, a preeminent virtual investor event, on January 27.
This elite event featured presentations from over 70 premier metals and mining stock market companies, as well as talks with industry experts.
1-18-2022 SRAX (NASDAQ: SRAX)
SRAX Announces Q4 Shares Repurchased and Dividend Payment
LOS ANGELES, Jan. 18, 2022 (GLOBE NEWSWIRE) — via InvestorWire — SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has announced the quantity of shares repurchased in the fourth quarter of 2021, as well as the first payment being made for the previously issued dividend.
Throughout the three months preceding December 31st, 2021, the Company repurchased approximately $800K worth of stock made up of 155,000 thousand shares of common stock at an average price of $5.12 per share. This was part of the Company’s $10 million share buyback program announced on August 17, 2021.
1-17-2022 Apollo Future Mobility Group (HK:860)
Greenridge Global Research provides Update
Changes to Board & Management Team. On Thursday, AFMG announced changes to the management team and Board, highlighted by the addition of Freeman Hui Shen as Co-Chairman of the Board. Mr. Shen is the founder, Chairman and CEO of WM Motor Group, a Chinese-based EV manufacturer, and largest shareholder of AFMG. Mr. Shen will also serve as Chair of the Nomination Committee and as a member of the Investment Committee of the Board. Joseph Lee was appointed as an Executive Director, Vice Chairman of the Board, and a member of the Investment Committee and Corporate Governance Committee. Mr. Lee brings over 15 years of private equity and investment banking experience to AFMG, will earn HK$200,000 per month in salary, and was granted 40,000,000 ten-year options exercisable at HK$0.44. Eric Ho will no longer serve as Chair of the Nomination Committee and will now serve as Co-Chairman instead of Chairman. With the reduction in shareholding and entrance of WM Motors, it is unclear how involved Mr. Ho will be going forward.
H2:21 Results. AFMG reported H2:21 Revenue of HK$287.5 million, well ahead of our estimate due to the higher than expected contribution from the legacy Jewellry business. The Auto business was lower than we expected, at HK$60.6 million, due to a delay in deliveries of two IE vehicles. As the Company has noted, the ESO business continues to build and it expanded last year to accommodate that growth. Operating expenses were roughly in line with our expectations. Non-operating expenses and losses in the period were mostly related to legacy assets or the contingent accounting for acquisitions. Net Loss for the period was HK$147.8 million, or HK$1.71 per diluted share.
Model Update. We shifted the two delayed IE deliveries into fiscal 2022 and added in the 125,000,000 ten-year stock option grant, exercisable at HK$0.445 into our model. We left everything else relatively unchanged as AFMG moves towards more rapid growth on multiple fronts.
Maintaining Rating & Target. The addition of Mr. Shen as Co-Chairman is a logical step to better align WM Motors and AFMG. We continue to believe the Company is significantly undervalued based on the sum of its parts, and expect that discount to fair value to decrease as its investment holdings move towards being publicly listed. We remain optimistic on AFMG’s potential and are reiterating our Buy rating and HK$1.50 target price on Apollo Future Mobility Group. Our target price is based on a P/E multiple of 25 times our fiscal 2023 Diluted EPS estimate of HK$5.75 cents, which falls just before the launch of the Apollo EVision S.
1-10-2022 SRAX (NASDAQ: SRAX)
Dawson James issues Research Update
Raising Estimates and Price Target to $13.00
|SRAX announced full year and Q1 revenue guidance far above our and consensus estimates. We are raising our estimates and price target, from $11.50 to $13.00 to reflect continued strong growth in the Sequire platform.|
We are raising our estimates for 2022 and our price target after the company announced revenue guidance for Q1 and the year far ahead of our and consensus estimates. For 2022 we are now projecting revenue of $45.5 million, at the low-end of company guidance of $46 to $48 million and an increase from our prior estimate of $38.4 million.
We estimate there were 250 Sequire customers at year-end 2021 and have modeled 415 by the end of 2022, an increase of 165, an acceleration from the 125 added in 2021. Average revenue per subscriber, per month, in 2021 was over $11,000. We have assumed this declines slightly, to $10,750 per month in 2022.
8-19-2021 SRAX (NASDAQ: SRAX)
Trickle Research issues Research Update
24 Month Price Target to $7.50
On 08/16/21, SRAX reported 2Q-F21 results, and those results and associated comments included a handful of interesting data points. We will try to briefly recap the most cogent of those.
First to recap, in some of our prior research we have tried to provide some pro forma glimpses of SRAX’s operations without the consolidation of BigToken. Recall, SRAX spun their BigToken division into a separate public company; Force Protection Video Equipment Corp. (OTC: FPVD) dba: BigToken. In short, because of their relative (majority) ownership of FPVD, SRAX is required to continue consolidating those results. Unfortunately, in our opinion, that consolidation continues to “muddy the water” and impedes the evaluation of SRAX in the context of its core Sequire business. Our hope is that they/BigToken will be able to execute an arrangement that will allow SRAX to report results that are not consolidated with those of FPVD.
The above noted, SRAX’s Sequire platform continues to gather momentum, so we will try to focus on that notion.
12-30-2021 CanB Corp (OTC CANB)
Can B Corp.’s Pure Health Products Awarded NSF’s GMP Certification
Independent Certification Enables the Company to Produce for Major Retailers Worldwide
HICKSVILLE, NY, Dec. 30, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, is pleased to announce that its Pure Health Products subsidiary has earned NSF International’s NSF/ANSI 455-2 dietary supplement GMP certification for its manufacturing facility in Lacey, Washington.
Marco Alfonsi, Can B’s Chief Executive Officer, stated, “This independent certification from the global public health organization demonstrates our commitment to personal care product quality and compliance with U.S. GMP requirements. It verifies that our manufacturing facility has the proper methods, equipment, facilities, and controls in place to produce dietary supplement products. The significance of the award is that it now allows us to process for any establishment throughout the planet.”
12-20-21 SRAX (NASDAQ: SRAX)
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced its entry into an advertising and media agreement for media buys and digital marketing with SRAX (NASDAQ: SRAX). Under the agreement, SRAX will act as the agent for Lexaria and will engage and manage media companies to create advertising materials and distribute them on internet platforms as well as manage the flow of such media distributions. SRAX will employ leading-edge analytical algorithms in order to maximize engagement. “Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long media outreach campaign,” said Chris Bunka, CEO of Lexaria Bioscience. “Lexaria has made tremendous progress during 2021 and we expect even more significant advancement in 2022 and are pursuing the broadest possible investor involvement to ensure that Lexaria’s achievements are communicated to all investors.”
Check out our latest commercial properties including an Amazing Private Island or Resort Development Property in Panama
Message me on Linkedin and check our latest commercial listings:
Please subscribe to our newsletter to get ongoing Real Estate and Alternative Investing updates:
|February 14, 2022 COMPANY QUOTES, LISTINGS RESEARCH AND NEWS Antibe Therapeutics, Inc (ATBPF) Profile 11/11/2018 News Can B Corp (CANB) Profile News Endurance Exploration Group, Ltd (EXPL) Profile 03-26/19 News Social Reality, Inc. (SRAX) Profile News Apollo Future Mobility Ltd. (HK 0860) Profile 2/23/2020 News|
ValuEngine Weekly Report
Is It Time for Actively Managed Value ETFs?
There is no sugarcoating it. January was a lousy month for the market. Many pundits are certain that this is the beginning of a yearlong downturn. Other experts are calling this a dip and a buying opportunity. Our models at ValuEngine are mixed with a six-month forecast on S&P 500 ETFs of +2.6% but a one-year forecast of -2.3%. The way we look at it, there’s no need to dump stocks now as you can lose a lot by being out of the market when it rises.
In the type of choppy market that may lie ahead and given the steep price-return decline of close to -7% in S&P 500 ETFs in January, it might be time to move some money from market-cap weighted index funds into some actively managed value-and-quality strategies geared to hold up better in volatile markets.
Read Complete Report
ValuEngine Capital Management LLC (VECM) is pleased to announce the addition of Jordan Kimmel to the team as the new Chief Equity Strategist and portfolio manager. VECM is a Registered Investment Advisor (RIA) that invests based on the proprietary, quantitative research produced by ValuEngine Inc. It is an important partnership between two companies: ValuEngine conducts research, and ValuEngine Capital Management LLC actively trades client funds using this research.
To subscribe to our bulletins and receive content whenever it is published, subscribe at our blog HERE
Black Swan Research Coverage and Subscription Service
Event Calendar Updates
SRAX to Host the 2022 Sequire Metals & Mining Virtual Conference on January 27th, 2022 a great success
LOS ANGELES, Jan. 13, 2022 (GLOBE NEWSWIRE) — via InvestorWire — SRAX, Inc. (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, announced it will host the first ever Sequire Metals & Mining Conference, a one-day investor event featuring prominent public mining companies and industry experts.
Rocky Mountain Microcap Conference VIII.
November 3, 2021 conference at TopGolf in Centennial Colorado was a great success with a higher than normal turnout.
Check it out and watch the presentations at:
LD Micro Main Event
October 12-14 Los Angeles.
This conference was a great success
All presenting company video calls will be available to view for 3 months. Visit the event website to see all the presentations: https://ldmicrojune2021.mysequire.com/
Check the website for updates:
Visit our homepage for up to the minute Financial News, Quotes and our Latest Black Swan Connection Newsletter
-SMM Distribution Update-
SMM Global Twitter Acct (Impressions last 30 days) 520
Direct Email * 220,000